Stock Price & Analysis

Based on the provided data and recent market activity, here's a concise analysis of NVS stock:

Technical Analysis

The stock shows a positive short-term trend, having gained 1.90% in the last trading session to close at $109.35. The stock has risen for 4 consecutive days and is up 2.22% over the past 2 weeks. Key technical indicators suggest:

• RSI reading of 27.29 indicates oversold conditions
• Trading volume increased with price movement, a positive technical signal
• Support levels at $105.48 and resistance at $109.81

Recent Analyst Actions

Two recent analyst ratings:

• BMO Capital (Feb 23, 2025): Hold rating with $114 price target
• Morgan Stanley (Jan 23, 2025): Hold rating with $114 price target

Both suggest approximately 14% upside potential from current levels.

Market Position & Valuation

• Market cap: $204.2B
• P/E ratio: 11.92
• The stock is currently trading in the upper part of a weak rising trend

Buy/Sell Decision

SELL recommendation based on:

1. Stock is approaching resistance level at $109.81
2. Currently trading near the upper bound of its recent range
3. Received a sell signal from pivot top point on February 5, 2025
4. MACD indicates a current sell signal

The stock's proximity to resistance levels and technical sell signals suggest it's better to wait for a pullback before establishing new positions.

Based on the available data and market analysis, here is the price prediction for NVS stock in 2025:

NVS stock is expected to reach $115-120 by end of 2025, representing a 5-10% upside from current levels, driven by strong pharmaceutical pipeline execution and continued market expansion. The company's robust fundamentals and defensive healthcare positioning support this moderate growth trajectory despite broader market uncertainties.

The prediction is based on:

1. Technical analysis shows NVS trading in an upward channel between $95-110 support and $115-120 resistance levels
2. Healthy pharmaceutical segment growth and pipeline developments provide fundamental support for continued appreciation

The S1 support level for NVS Stock is $105.79 ,The R1 resistant level for NVS Stock is $111.6.

As of the end of day on 2025-02-26, the price of NVS Stock was $108.02.

The target price for NVS Stock according to analyst rating is 140.50, with the highest price target at 156.00 and the lowest at 125.00. Analysts have a Moderate Buy rating on NVS Stock overall.

The market cap of NVS is $236.6B.

Based on the provided data and current valuation metrics, here is a concise analysis of whether NVS is overvalued:

Novartis (NVS) appears fairly valued considering its current fundamentals and growth prospects. The company's P/E ratio has improved from 31.18x in 2022 to 24.65x in 2023, indicating better earnings efficiency. The EV/EBITDA multiple of 12.27x is reasonable for the pharmaceutical sector.

Net income doubled from $6.96B in 2022 to $14.85B in 2023, demonstrating strong profit growth. ROE increased significantly from 9.53% to 16.16%, showing improved capital efficiency.

The company maintains stable margins with gross margin at 74.24% and net margin expanding to 18.37% in 2023, reflecting operational effectiveness.

Technical indicators show RSI at 64.86, suggesting momentum but not yet overbought territory. The stock is trading above its 60-day SMA of $101.83, indicating positive trend strength.

The current valuation appears justified given Novartis's strong financial performance, improved profitability metrics, and positive technical indicators.

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Based on the provided data and market analysis, here is the price prediction for NVS stock by 2030:

Novartis AG (NVS) stock is projected to reach $121.54 by 2030, representing an approximate 11% increase from the current price of $109.35. This moderate growth forecast is supported by the company's strong fundamentals in biotechnology and pharmaceuticals, with high ratings from investment models like Validea's Multi-Factor Investor model showing 81% confidence.

Key Growth Drivers:

• Strong momentum and high net payout yields indicate significant market interest
• Conservative factor investing strategy suggests lower volatility compared to peers
• Diversified pharmaceutical portfolio reducing business risk
• Potential growth from new drug developments and market expansions

Growth Path Projection:

• 2025: Average price of $105.71 with range $97.93-$114.09
• 2026-2029: Steady annual growth rate between 3-4%
• 2030: Target price of $121.54

The projection considers both technical indicators and fundamental factors, suggesting a relatively stable but modest growth trajectory for NVS over the next 5 years. The conservative growth estimate reflects the defensive nature of pharmaceutical stocks and Novartis's established market position.

NVS has a total of 76057 employees.